GlassScriptPhysician profile
Sukhpreet Kaur
NPI 1699352161
$1,285.01
in general payments reported to CMS, 2019-2025
8 companies · $1,252 in 2025
The $1,252 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $33.31 · 2025: $1,252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $743 · Travel and Lodging: $303 · Education: $239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $743.03 |
| Travel and Lodging | $303.47 |
| Education | $238.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $654.32 | 2024-2025 | |
| Abbott Laboratories | $238.51 | 2025 | Ensite |
| Shockwave Medical, INC | $140.92 | 2025 | |
| Inari Medical, INC. | $125.01 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Boston Scientific Corporation | $49.64 | 2025 | Watchman |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $43.30 | 2025 | Lifevest |
| United Therapeutics Corporation | $17.59 | 2025 | Remodulin, Orenitram |
| Astrazeneca Pharmaceuticals LP | $15.72 | 2025 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sukhpreet Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.